首页> 外文期刊>Genetic testing and molecular biomarkers >Test Performance of Sputum microRNAs for Lung Cancer: A Meta-Analysis
【24h】

Test Performance of Sputum microRNAs for Lung Cancer: A Meta-Analysis

机译:肺癌痰液微RNA的检测性能:一项荟萃分析

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Lung cancer is the leading cause of cancer-related deaths worldwide. Early detection and precise diagnosis are critical for the patients with lung cancer. Increasing evidence has suggested that microRNAs (miRNAs) play important roles in the diagnosis of lung cancer. To evaluate the overall diagnostic performance of sputum miRNAs for the detection of lung cancer, a meta-analysis was performed. Methods: A systematic search for published literature evaluating the diagnostic accuracy of sputum miRNAs in lung cancer was performed to determine pooled sensitivity and specificity. A summary receiver operating characteristic curve was constructed to assess the overall test performance. Subgroup analysis was utilized to explore potential sources of heterogeneity in the included studies. Results: Eight studies with a total of 514 patients and 491 controls were included in this meta-analysis. Sputum miRNAs had a pooled sensitivity of 0.70 (95% confidence interval [95% CI]: 0.66-0.70) and a pooled specificity of 0.89 (95% CI: 0.86-0.91) for the detection of lung cancer, with an area under the summary receiver operating characteristics curve of 0.83. Significant interstudy heterogeneity for specificity was observed, with miRNA profiles being a possible source. Conclusion: Sputum miRNAs are potentially useful noninvasive markers for diagnosis of lung cancer. The diagnostic specificity of sputum miRNAs may be influenced by the miRNA profiles. It would be important for further work to evaluate the generalizability of our results by methodologically rigorous studies on a well-defined patient population.
机译:背景:肺癌是全球癌症相关死亡的主要原因。早期发现和精确诊断对于肺癌患者至关重要。越来越多的证据表明,microRNA(miRNA)在肺癌的诊断中起着重要的作用。为了评估痰液miRNA对肺癌检测的总体诊断性能,进行了荟萃分析。方法:系统地搜索已发表的文献,评估痰中miRNA在肺癌中的诊断准确性,以确定合并的敏感性和特异性。构造了摘要接收器工作特性曲线以评估总体测试性能。利用亚组分析来探讨纳入研究中潜在的异质性来源。结果:这项荟萃分析包括八项研究,共514名患者和491名对照。痰液miRNA联合检测肺癌的敏感性为0.70(95%置信区间[95%CI]:0.66-0.70),联合特异性为0.89(95%CI:0.86-0.91),面积在摘要接收器的工作特性曲线为0.83。观察到特异性之间的研究间显着异质性,可能是miRNA谱。结论:痰中的miRNAs是诊断肺癌的潜在有用的非侵入性标志物。痰液miRNA的诊断特异性可能会受到miRNA谱的影响。通过对定义明确的患者群体进行严格的方法学研究来评估我们的研究结果的推广性,对于进一步的工作很重要。

著录项

  • 来源
    《Genetic testing and molecular biomarkers》 |2014年第8期|562-567|共6页
  • 作者单位

    Experimental Teaching Center of Preventive Medicine, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, People's Republic of China;

    Experimental Teaching Center of Preventive Medicine, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, People's Republic of China;

    Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, People's Republic of China;

    Hygiene Detection Center, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, People's Republic of China;

    Experimental Teaching Center of Preventive Medicine, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, People's Republic of China;

    Experimental Teaching Center of Preventive Medicine, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, People's Republic of China;

    Experimental Teaching Center of Preventive Medicine School of Public Health and Tropical Medicine Southern Medical University No. 1838 Guangzhou Avenue North Guangzhou 510515 People's Republic of China;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 13:16:43

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号